Brokerages forecast that Meridian Bioscience, Inc. (NASDAQ:VIVO) will announce $49.81 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Meridian Bioscience’s earnings. The highest sales estimate is $50.36 million and the lowest is $49.30 million. Meridian Bioscience reported sales of $51.74 million during the same quarter last year, which indicates a negative year-over-year growth rate of 3.7%. The business is scheduled to issue its next earnings report before the market opens on Tuesday, July 30th.

On average, analysts expect that Meridian Bioscience will report full-year sales of $202.38 million for the current fiscal year, with estimates ranging from $200.90 million to $203.78 million. For the next financial year, analysts expect that the company will report sales of $206.55 million, with estimates ranging from $205.50 million to $208.06 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. The business had revenue of $50.25 million for the quarter, compared to analysts’ expectations of $50.03 million. Meridian Bioscience had a net margin of 13.29% and a return on equity of 18.58%. The company’s revenue was down 11.0% compared to the same quarter last year. During the same period last year, the business earned $0.21 EPS.

A number of analysts recently commented on VIVO shares. Zacks Investment Research upgraded shares of SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Friday, July 5th. Robert W. Baird started coverage on shares of Carbon Black in a research report on Wednesday, April 3rd. They set an “outperform” rating and a $20.00 price target for the company. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. ValuEngine raised shares of Yandex from a “hold” rating to a “buy” rating in a research report on Saturday, April 13th. Finally, Canaccord Genuity reissued a “buy” rating and set a $1.80 price target on shares of Meridian Bioscience in a research report on Wednesday, June 5th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.45.

In other news, Director James M. Anderson bought 5,000 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was purchased at an average cost of $11.37 per share, with a total value of $56,850.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John P. Kenny bought 20,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were purchased at an average cost of $11.49 per share, with a total value of $229,800.00. Following the completion of the acquisition, the chief executive officer now owns 83,000 shares in the company, valued at $953,670. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 32,000 shares of company stock valued at $366,170. Insiders own 2.00% of the company’s stock.

Several large investors have recently bought and sold shares of VIVO. LPL Financial LLC boosted its position in shares of Meridian Bioscience by 4.4% during the fourth quarter. LPL Financial LLC now owns 22,259 shares of the company’s stock worth $386,000 after acquiring an additional 934 shares during the last quarter. BlackRock Inc. boosted its position in shares of Meridian Bioscience by 1.1% during the fourth quarter. BlackRock Inc. now owns 6,295,660 shares of the company’s stock worth $109,294,000 after acquiring an additional 67,044 shares during the last quarter. Texas Permanent School Fund boosted its position in shares of Meridian Bioscience by 4.0% during the fourth quarter. Texas Permanent School Fund now owns 27,748 shares of the company’s stock worth $482,000 after acquiring an additional 1,073 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Meridian Bioscience during the fourth quarter worth $939,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Meridian Bioscience by 0.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,901,563 shares of the company’s stock worth $33,011,000 after acquiring an additional 14,871 shares during the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

VIVO stock traded up $0.01 during trading on Tuesday, reaching $11.58. The company had a trading volume of 222,408 shares, compared to its average volume of 299,843. The business has a 50-day simple moving average of $11.56. The firm has a market cap of $492.02 million, a P/E ratio of 15.65 and a beta of 0.33. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.31 and a current ratio of 6.01. Meridian Bioscience has a twelve month low of $10.77 and a twelve month high of $19.84.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Featured Story: Overbought

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.